Coming Soon: Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
September 29th 2023Expert Matthew Lunning, DO, FACP, shares his excitement for an upcoming case-based peer perspectives program wherein he reviews the diagnosis and management of a patient with DLBCL, considering evolving treatment paradigms and updated clinical data.
Watch
CAR T Cells and Bispecifics Generate Excitement in Multiple Myeloma
September 29th 2023Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Watch
Case Overview: A 62-Year-Old Woman with Squamous Histology and PD-L1 Negative mNSCLC
September 29th 2023Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.
Watch
Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS
September 29th 2023Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.
Watch
The Future of Patient Care in RRMM
September 28th 2023Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.
Watch
Toxicity Management for Emerging Bispecifics in Patients With RRMM
September 28th 2023Ajai Chari, MD, discusses managing toxicities in patients with relapsed/refractory multiple myeloma treated with emerging bispecific therapies, emphasizing common adverse events including cytokine release syndrome, target-related toxicities such as neutropenia, and mitigation strategies such as pre-medication, early intervention with tocilizumab, and dose modulation.
Watch
Petrylak Reviews Results From KEYNOTE-921 in mCRPC
September 28th 2023Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Watch
Emerging Treatments for Patients With RRMM: Data From CARTITUDE-1
September 28th 2023Dr Ajai Chari highlights the CARTITUDE-1 study for its impressive results in the treatment of patients with relapsed/refractory multiple myeloma, noting a high response rate after three-year updates, which led to the accelerated approval of cilta-cel therapy.
Watch
Talquetamab in Patients With RRMM: Key Takeaways From MontumenTAL-1
September 28th 2023Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.
Watch
Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
September 28th 2023Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.
Watch
Closing Thoughts on Data Updates From IASLC 2023 World Conference on Lung Cancer
September 21st 2023Following their review of data from the IASLC 2023 World Conference on Lung Cancer with expert Stephen Liu, MD, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, highlight key takeaways and future directions in care.
Watch